Abstract
To evaluate the role of AMP nasal challenge as a measure of short-term treatment response in patients receiving intranasal corticosteroids. Adenosine monophosphate (AMP) challenge has been shown to be a good inflammatory surrogate in the lower airways, but it has not been properly evaluated as a nasal challenge test.
Original language | English |
---|---|
Pages (from-to) | 354-9 |
Number of pages | 6 |
Journal | British Journal of Clinical Pharmacology |
Volume | 55 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2003 |